World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
70
Citations
15035
World Ranking
2441
National Ranking
1166

Overview

Daniel A. Vallera is affiliated with the University of Minnesota in the United States. Their research spans multiple fields, with a focus on medicine, immunology and microbiology, as well as biochemistry, genetics, and molecular biology. Their work often intersects with subfields such as immunology, oncology, pulmonary and respiratory medicine, hematology, and biotechnology.

The research topics Vallera has contributed to include:

  • Immune Cell Function and Interaction
  • CAR-T cell therapy research
  • Veterinary Oncology Research
  • Cancer Research and Treatments
  • Virus-based gene therapy research
  • T-cell and B-cell Immunology
  • Acute Myeloid Leukemia Research

Among their frequent collaborators are:

  • Martin Felices
  • Jaime F. Modiano
  • Jeffrey S. Miller
  • Sara Pracht
  • Antonella Borgatti

Their publications appear predominantly in journals such as Hematological Oncology, Regular and Young Investigator Award Abstracts, Cancer Research, Blood Advances, and Cancers. These venues reflect their concentration on clinical and experimental studies in hematology, oncology, and immunology.

Notable recent publications by Daniel A. Vallera include:

  • "A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells" (2020, Leukemia)
  • "Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML" (2020, Blood Advances)
  • "NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo" (2020, Cancers)
  • "Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager" (2020, Cancer Immunology Research)
  • "Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia" (2021, Molecular Therapy)

Their research often centers on immunotherapy approaches, particularly involving natural killer (NK) cells and killer engagers, with applications in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and solid tumors.

Best Publications

  • Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia.

    John H. Kersey;Daniel Weisdorf;Mark E. Nesbit;Tucker W. LeBien

  • In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice

    Bruce R Blazar;Patricia A. Taylor;Peter S. Linsley;Daniel A Vallera

  • IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

    Daniel A. Vallera;Martin Felices;Ron McElmurry;Valarie McCullar

  • Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

    Qing Zhou;Meghan E. Munger;Steven L. Highfill;Jakub Tolar

  • CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

    Michelle K. Gleason;Julie A. Ross;Erica D. Warlick;Troy C. Lund

  • Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.

    William J Murphy;Lisbeth A. Welniak;Dennis D. Taub;Robert H. Wiltrout

  • 3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments.

    Fanben Meng;Carolyn M. Meyer;Daeha Joung;Daniel A. Vallera

  • Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition

    Andres Wiernik;Bree Foley;Bin Zhang;Michael R. Verneris

  • Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

    Michelle K. Gleason;Michael R. Verneris;Deborah A. Todhunter;Bin Zhang

  • Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease.

    A.H Filipovich;A.H Filipovich;R.J Youle;R.J Youle;D.M Neville;D.M Neville;D.A Vallera;D.A Vallera

  • Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.

    Bruce R. Blazar;Patricia A. Taylor;Angela Panoskaltsis-Mortari;Janet Buhlman

  • Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies

    Daniel A. Vallera;Robert C. Ash;Esmail D. Zanjani;John H. Kersey

  • Keratinocyte Growth Factor Administered Before Conditioning Ameliorates Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation in Mice

    Angela Panoskaltsis-Mortari;Angela Panoskaltsis-Mortari;David L. Lacey;David L. Lacey;Daniel A. Vallera;Daniel A. Vallera;Bruce R. Blazar;Bruce R. Blazar

  • Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts.

    Bruce R. Blazar;Patricia A. Taylor;Sidney Smith;Daniel A. Vallera

  • Recent advances in graft-versus-host disease (GVHD) prevention

    Bruce R. Blazar;Robert Korngold;Daniel A. Vallera

  • Opposing Roles of CD28:B7 and CTLA-4:B7 Pathways in Regulating In Vivo Alloresponses in Murine Recipients of MHC Disparate T Cells

    Bruce R. Blazar;Patricia A. Taylor;Angela Panoskaltsis-Mortari;Arlene H. Sharpe

  • Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia.

    Fatih M. Uckun;Kazimiera J. Gajl-Peczalska;John H. Kersey;Lou L. Houston

  • Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.

    Bruce R. Blazar;Arlene H. Sharpe;Patricia A. Taylor;Angela Panoskaltsis-Mortari

  • Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts

    Bruce R. Blazar;Patricia A. Taylor;Angela Panoskaltsis-Mortari;Gary S. Gray

  • THE CRITICAL EARLY PROINFLAMMATORY EVENTS ASSOCIATED WITH IDIOPATHIC PNEUMONIA SYNDROME IN IRRADIATED MURINE ALLOGENEIC RECIPIENTS ARE DUE TO DONOR T CELL INFUSION AND POTENTIATED BY CYCLOPHOSPHAMIDE

    A Panoskaltsis-Mortari;P A Taylor;T M Yaeger;O D Wangensteen

Frequent Co-Authors

Bruce R. Blazar
Bruce R. Blazar University of Minnesota
Patricia A. Taylor
Patricia A. Taylor University of Minnesota
Jeffrey S. Miller
Jeffrey S. Miller University of Minnesota
Angela Panoskaltsis-Mortari
Angela Panoskaltsis-Mortari University of Minnesota
Daniel J. Weisdorf
Daniel J. Weisdorf University of Minnesota
John H. Kersey
John H. Kersey University of Minnesota
Fatih M. Uckun
Fatih M. Uckun University of Southern California
Norma K.C. Ramsay
Norma K.C. Ramsay University of Minnesota
Michael R. Verneris
Michael R. Verneris University of Colorado Denver
Jaime F. Modiano
Jaime F. Modiano University of Minnesota

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in pursuing Immunology in the USA, exploring related online degrees and career pathways can be highly beneficial. Many students in the healthcare field begin their journey through nursing programs, which offer various accelerated options for quicker entry into the profession.

One popular route is through accelerated rn to np programs. These programs allow registered nurses to fast-track their education and become nurse practitioners with advanced clinical knowledge—skills that are valuable in immunology-related healthcare settings.

For individuals without a prior nursing background, online absn programs for non nurses provide a direct pathway into nursing. These degrees offer flexible learning options and prepare students for foundational roles in patient care and research.

Additionally, some may benefit from exploring 12-month accelerated nursing programs, which deliver comprehensive nursing education within a short timeframe. These intensive programs are designed to meet high demand for nursing professionals in healthcare and research fields.

Those seeking entry-level positions might consider easy admission lpn programs. Licensed Practical Nurse programs are often more accessible and can serve as a stepping stone toward advanced roles in immunology-related care and study.

Best Scientists Citing Daniel A. Vallera

Trending Scientists

Recently Published Articles